Skip to main content
Premium Trial:

Request an Annual Quote

Provista Closes $5.25M Financing

NEW YORK (GenomeWeb) – Provista Diagnostics said today that it has closed $5.25 million in preferred funding generated by existing investors exercising warrants from a previous financing round.

The firm plans to use the money for continued commercial development and clinical testing of its proteomic diagnostics, as well as for management hires and general corporate purposes.

New York City-based Provista specializes in women's cancers — its lead product, the Videssa Breast cancer test, is a proteomic blood test intended for use with imaging to aid early detection of breast cancer. The company plans to launch the test this year out of its CLIA lab.

The company also said it has raised a total of $37.9 million since 2011.